The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies
- 1 September 2011
- journal article
- review article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 65 (3) , 624-635
Abstract
No abstract availableKeywords
Funding Information
- Dermatology Foundation.
- Bristol Myers Squibb, Boehringer Ingelheim, ImClone/Eli Lilly, Onyx, Bayer, Genzyme, Amgen, and Threshold.
- Hana Biosciences and Onyx Pharmaceuticals.
This publication has 82 references indexed in Scilit:
- Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancerOncogene, 2007
- Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapyCell Research, 2007
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- The Hallmarks of CancerCell, 2000
- Muromonab CD3Drugs, 1989
- Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory CompoundsNature, 1957
- NITROGEN MUSTARD THERAPYJAMA, 1946
- The Biological Actions and Therapeutic Applications of the B-Chloroethyl Amines and SulfidesScience, 1946
- Priority in the Therapeutic Use of X-raysRadiology, 1933